In Part 4 of this video series, Rana McKay, MD, Medical Oncologist and Associate Professor of Medicine, UC San Diego Health, summarizes the novel therapies or optimal sequencing patterns that are under investigation or close to entering the metastatic RCC treatment space, as well as triplet therapy regimens to keep an eye on.
Among the mentioned studies were STELLAR-001 and STELLAR-002, STARLITE-1 and STARLITE-2, and a few others that may lead to Food and Drug Administration approval soon.
View Dr. McKay’s other comments on advanced RCC management, including the Current Treatment Paradigm, Frontline Immunotherapy, Second-line Therapy and Beyond, and Radiation Therapy and Radiopharmaceuticals.